Comparative 3-year Study of Nissen-sleeve vs. Sleeve Plus Cruroplasty in Obese Patients With Hiatal Hernia

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorElsan

About this trial

The success of laparoscopic sleeve gastrectomy (LSG) is not only due to its proven efficacy in the treatment of obesity and associated to comorbidities in the short and long term, but also because it is considered as less technically complicated compared to other malabsorptive procedures. Unfortunately, the main long-term side effect of LSG appears to be the development of severe gastroesophageal reflux (GERD). This problem is aggravated by the concomitant presence of a hiatal hernia at the time of surgery. Indeed, by causing laxity of the lower esophageal sphincter (LES), the hiatal hernia reduces the barrier functions of the esophageal-gastric junction against the reflux of gastric contents.

The classic combination of sleeve and hiatal hernia treatment by cruroplasty gives contradictory results and several surgeons prefer to perform only the sleeve without addressing the hiatal hernia especially if it is small (\<4 cm). For this reason a modification of the usual surgical technique of LSG has been proposed by adding a Nissen fundoplication-Nissen Sleeve (NS). The intentions of this technique were to minimize the rate of postoperative GERD especially for patients with hiatal hernia, to protect the staple line of the angle of His, and finally to provide a safe and effective alternative for patients with a contraindication to LRYGB due to GERD. Although the first results of the technique are encouraging, the realization of the Nissen valve remains a sensitive technical point that can transform a relatively simple procedure like LSG into a more complex procedure like NS. The only test able to directly identify and classify gastric reflux is pH-metry with or without esophageal manometry. Unfortunately, especially due to the difficulty of access to the examination, there are no studies with solid scientific bases that identify the correct conduct to adopt in the case of an obese patient with a hiatal hernia (with or without preoperative reflux).

The main objective of this study is to evaluate the occurence or worsening of GERD at 3 years following a Nissen-sleeve vs. sleeve plus cruroplasty intervention in patients with obesity and hiatal hernia.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult patient,

Patient with severe obesity (BMI >35) with comorbidity or morbidity (BMI >40),

Patient awaiting a sleeve gastrectomy,

Patient with a hiatal hernia <or= 4 cm,

Disqualifiers

Patient with poorly controlled diabetes,

Patient with major esophageal motility disorders,

Patient with a Hiatal Hernia > 4cm,

History of bariatric surgery, history of ring,

Trial design

Design model

Parallel

Treatments tested in this trial

  • Ph-measurement

    Diagnostic test

    Ph measurement before and after the surgery

  • Questionnaires

    Other intervention

    GERD-HRQL Reflux symptom index scale before and after surgery

  • gastroduodenal transit

    Diagnostic test

    Imaging test that uses the properties of X-rays - after the administration of a radiopaque contrast agent (usually barium) - to visualize the upper digestive tract: the esophagus, stomach, and duodenum (the upper segment of the small intestine).

Treatment groups

150 Participants
are divided into 2 treatment groups
Group A: Nissen sleeve surgeryExperimental treatment 3 interventions
Group B: Sleeve plus cruroplastyActive comparator 3 interventions

Trial outcomes

Primary outcomes

1

Appearance of GERD 3 years after surgery.

Occurrence if DeMeester score at 3 years is ≥ 14.72 (\<14.72 before surgery) and/or treatment with proton pump inhibitors (PPIs) and/or Reflux Disease Questionnaire score \> 10 (≤10 before surgery) and/or GERD-HRQL score \> 16 (≤16 before surgery).

Time frame
3 years
2

Worsening of GERD 3 years after surgery.

Worsening if increase in DeMeester score at 3 years compared to that before the intervention and/or introduction or increase in the dose of PPI compared to that before the intervention and/or increase in the Reflux Disease Questionnaire score at 3 years compared to that before the intervention and/or increase in the GERD-HRQL score at 3 years compared to that before the intervention.

Time frame
3 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Elsan

Lead sponsor

Clinique saint-Michel de Toulon

Collaborator

This trial is not recruiting at the moment. You can still explore other options: